Exploristics | Transforming Clinical Trial Design

🚀 As a proud silver-accredited Diversity Mark organisation, Exploristics is excited to join Northern Ireland’s largest EDI-focused event, the Diversity Mark Annual Summit on 8th October at Titanic Belfast! Our Head of Business Operations Frances D. will be in attendance to connect with 300 business leaders and diversity champions. With the theme ‘EDI 2.0: From Action to Impact,’ we’re looking forward to sharing our own perspectives and learning from expert speakers to continue driving inclusion within the workplace. Book a meeting with Frances here: https://lnkd.in/dNb5vZca #Exploristics #SilverAccredited #InclusiveBusiness #DiversityMarkSummit #EDISummit2024

Join Exploristics for a webinar that explores how robust biostatistics is pivotal in investment decisions for biotechs. We’ll discuss strategies to leverage data-driven insights to build investor confidence to secure the financial backing needed for growth and innovation. Our esteemed panel features Exploristics CEO Aiden Flynn, Non-Executive Director Susan Clement Davies, and Victoria Manax Rutson, MD, Partner at Eckuity Capital. Together, they bring decades of combined expertise in biotech, medical research, and investment, offering valuable knowledge from their extensive industry experience on successful biotech funding. Whether your biotech organisation is seeking investment or aiming to strengthen investor confidence, this session will provide the secret sauce for early-stage funding. Key topics covered: 🔍 What Investors Look For– The Role of Data and Confidence 📊 Case studies where biostatistics have driven successful investment decisions 📈 The Role of Biostatistics in De-Risking Early-Stage Biotech Investments ✨ Biosimulation and its Impact on Investment Decisions ❓ Q&A session

"Management teams need to have road tested their clinical development plans and the role of data informed decisions will support investor confidence" Susan Clement Davies joins us to explore how robust biostatistics is pivotal in investment decisions for biotechs. Susan Clement Davies is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including as Managing Director at Salomon Smith Barney/Citigroup Global Markets. Susan is currently Non-Executive Director and Deputy Chair of the Audit Committee of Scancell Holdings Plc, a developer of novel immuno-oncology therapies, Non-Executive Director and Chairman of the Remuneration Committee at Science Group PLC, an international science & technology consultancy and systems organisation, Non-Executive Director and Chairman of the Audit Committee at MiNA Therapeutics focused on RNAa in genetic medicine, Adviser to Oxford Science Enterprises and is on the Innovations Advisory Board at Chelsea & Westminster NHS Trust Hospital. Register for our upcoming webinar on Thursday 3rd October here: https://lnkd.in/d_UCRUtb

“So many clinical development failures could be completely avoided through further investment in planning and design. Statisticians quantify the risks and help to put in place strategies to minimise them."   Aiden Flynn will be hosting our upcoming webinar as we explore how robust biostatistics is pivotal in investment decisions for biotechs.    At Exploristics, Aiden has created an innovative and profitable company and overseen its ongoing growth and transition from a specialist statistics consultancy to a provider of innovative statistical software such as the KerusCloud platform with wrap-around biostatistics support. As such, Exploristics caters to a wide range of global healthcare developers from the world’s top pharmaceutical companies to biotechnology, medical device and diagnostic start-ups.   With key expertise in emerging approaches to clinical development such as Precision Medicine and biomarker discovery, validation and integration, Aiden has worked closely with regulatory authorities, such as the FDA and EMA, to develop tools and guidelines that support the use of biomarkers in clinical studies. He has over 40 publications in peer reviewed journals and books and is an invited speaker at international conferences.   Aiden is also a member of the Precision Medicine Advisory Board at Merck Biopharma and is involved in the Precision Medicine Steering Group, offering strategic advice to the Department of Health. Aiden is also Commercial Director on the Board of Directors at PSI. Register for our upcoming webinar on Thursday 3rd October here: https://lnkd.in/d_UCRUtb

“As an investor, one of the first things I look for in a biotech company is the relationship between the CMO and the statistician. If they can’t demonstrate a strong, collaborative partnership, then that’s a red flag”. Dr. Victoria Manax Rutson, MD joins us to explore how robust biostatistics is pivotal in investment decisions for biotechs. An accomplished medical oncologist with over two decades of expertise in the pharmaceutical/biotech industry, focusing on global drug/device development, nanomedicines, and product launch/commercialization. She has made indelible contributions to the field, particularly in shaping clinical trial landscapes with adaptive platform designs and biomarker integration. Renowned for her innovative clinical trial designs, Dr. Manax played a pivotal role in the development, approval, and launch of billion-dollar products, including the standard of care for pancreatic cancer. Holding multiple executive positions in companies such as Celgene (BMS), Immunicom, and Duo Oncology, she has also served as the inaugural Chief Medical Officer for the PancreaticnCancer Action Network, earning recognition as a respected panelist among FDA and regulatory agencies worldwide. Effectively overseeing numerous multimillion-dollar global clinical trial programs, Dr. Manax holds multiple clinical advisories, chair positions, and patents, exemplifying her commitment to advancing medical science and patient well-being. Over the last 16 years, Victoria has actively syndicated and participated in a range of investments, spanning venture debt, medical real estate, and Class A multifamily assets. Her strategic approach has led to the creation of a robust portfolio with an asset value surpassing $200 million. Register for our upcoming webinar on Thursday 3rd October here: https://lnkd.in/d_UCRUtb

🔍 Unlock Precision Medicine Success with KerusCloud 🚀 Discover how Exploristics' KerusCloud transforms the way precision medicine strategies are designed and executed in clinical trials. In this case study, you’ll learn how KerusCloud helped a sponsor improve the probability of success (PoS) in a Phase IIb Alzheimer’s study by evaluating both retrospective and prospective study designs. Through advanced simulation, KerusCloud nearly doubled the PoS without increasing sample size or costs, showcasing the power of smarter study designs. Read the full case study to see how KerusCloud can boost your precision medicine strategies. Learn more🔗 : https://lnkd.in/eP5fkJAt #PrecisionMedicine #ClinicalTrials #KerusCloud #Biotech #StudyDesign #PersonalizedMedicine #DrugDevelopment #ClinicalResearch

🚀 Demonstrating Statistical Concepts to GCSE Students! 🎓🔢 While many software applications aim to simplify complexity for users, our goal was different—we wanted to teach that complexity to students. Our modal to teach randomisation combines Shiny Modules, JavaScript & CSS to create bespoke pop-up providing visual aids, prompts for classroom discussions and bespoke data visualisation based upon data the students have collected. Come to Jumping Rivers Ltd #Shiny in Production to hear about the interactive Shiny application we’re developing as part of the PSI: Statisticians in the Pharmaceutical Industry Schools Outreach Initiative, that helps GCSE students understand the statistical concepts and principles. Thanks to Exploristics | Transforming Clinical Trial Design, Alex Spiers Emma Crawford Steve Mallett Katie Gwinnell My Luong Vuong 👇 Links in comments 👇

An IDMC is a panel of independent experts who operate outside a study to assess its progress, safety data, and in some cases, the critical efficacy endpoints. Their role is to ensure that the ethical and clinical interests of study patients are prioritised, and that their participation provides a favorable benefit-risk ratio. IDMCs also ensure the scientific integrity of the study throughout its duration, from initiation to completion. Discover whether your study needs an IDMC and the key factors to consider when making this decision below. Learn more about Exploristics IDMC services today: https://lnkd.in/dhFRmsJs #Pharma #Biotech #ClinicalDevelopment #IDMC #Biostatistics

Our friends at Exploristics | Transforming Clinical Trial Design our hosting an online event. Save the date Date: October 3rd Join Exploristics for a webinar that explores how robust biostatistics is pivotal in investment decisions for biotechs. They’ll discuss strategies to leverage data-driven insights to build investor confidence to secure the financial backing needed for growth and innovation. The esteemed panel features Exploristics CEO Aiden Flynn, Non-Executive Director Susan Clement Davies, and Victoria Manax Rutson, MD, Partner at Eckuity Capital. Together, they bring decades of combined expertise in biotech, medical research, and investment, offering valuable knowledge from their extensive industry experience on successful biotech funding. Whether your biotech organisation is seeking investment or aiming to strengthen investor confidence, this session will provide the secret sauce for early-stage funding. Key topics covered: 🔍 What Investors Look For– The Role of Data and Confidence 📊 Case studies where biostatistics have driven successful investment decisions 📈 The Role of Biostatistics in De-Risking Early-Stage Biotech Investments ✨ Biosimulation and its Impact on Investment Decisions ❓ Q&A session Sign up here - https://lnkd.in/gWPj6gqw

⛳ Exploristics Takes on Mini Golf! ⛳ What better way to bond than with a little competition? Our Belfast team has kicked off a mini golf tournament, planning to complete all local courses before Christmas! Leading the charge, Moira Murphy and Matthew Cohen are tied with 45 strokes, with Joseph Morgan and Amy McCorry, PhD right behind at 46. Who will emerge victorious? Stay tuned for more updates as the tournament continues! #TeamBuilding #MiniGolfAdventure #BelfastEvents #FriendlyCompetition